Volume 148, Issue 1, Pages (January 2018)

Slides:

Advertisements

Similar presentations

Rate of breast cancer-specific survival Months Low gene expression (N=252) High gene expression (N=37) P < (Log-rank) a Months Low gene expression.

Advertisements

Prognostic impact of Ki-67 in Croatian women with early breast cancer (single-institution prospective observational study) Ivan Bilić, Natalija Dedić Plavetić,

Uterine serous carcinoma is more aggressive than high-grade serous ovarian carcinoma: a retrospective study H. Nagano1, Y. Tachibana1, M. Kawakami1, M.

Nicoletta Colombo, Martin Gore

Volume 144, Issue 1, Pages (January 2017)

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial) M. Yoshida, K. Muro, A. Tsuji,

Picture 3. Higher grade tumors are more frequently Ki67 positive

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer Ana Belén Custodio, MD, José Luis González-Larriba,

Volume 119, Issue 4, Pages (October 2000)

Volume 149, Issue 2, Pages (May 2018)

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Volume 145, Issue 1, Pages (April 2017)

Volume 148, Issue 1, Pages (January 2018)

Tumor volume predicts local recurrence in early rectal cancer treated with radical resection: A retrospective observational study of 270 patients Yanhui.

Volume 148, Issue 1, Pages (January 2018)

Are patients willing to travel for better ovarian cancer care?

Volume 148, Issue 1, Pages (January 2018)

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

Volume 148, Issue 1, Pages (January 2018)

Volume 146, Issue 3, Pages (September 2017)

Volume 150, Issue 3, Pages (September 2018)

A. Melamed, E. J. Diver, A. A. Gockley, E. M. Hinchcliff, L

Pain in cancer survivors; filling in the gaps

Volume 145, Issue 2, Pages (May 2017)

Vulvar intraepithelial neoplasia: Risk factors for recurrence

Volume 119, Issue 4, Pages (October 2000)

Patient-reported symptoms and performance status before palliative radiotherapy in geriatric cancer patients (octogenarians) Carsten Nieder, Thomas A.

Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis M. Proesmans, F. Vermeulen,

Adjuvant chemotherapy for rectal cancer – Authors' reply

Volume 152, Issue 1, Pages (January 2019)

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy Apar Pataer, MD, PhD, Neda Kalhor,

Volume 141, Issue 2, Pages (May 2016)

The development and use of vascular targeted therapy in ovarian cancer

Volume 145, Issue 2, Pages (May 2017)

National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence J. Chino, J.R. Foote,

Volume 146, Issue 1, Pages (July 2017)

Volume 91, Issue 3, (December 2003)

Thymoma: A Population-Based Study of the Management and Outcomes for the Province of British Columbia Caroline Mariano, MD, Diana N. Ionescu, MD, Winson.

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

Volume 151, Issue 1, Pages (October 2018)

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 143, Issue 2, Pages (November 2016)

Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)

Survival and failure types after radiation therapy of vulvar cancer

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum A. Ellis, M.K. Frey, L.M. Koontz, S. Shyne,

Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients treated with adjuvant chemotherapy after.

Volume 152, Issue 1, Pages (January 2019)

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Volume 152, Issue 1, Pages (January 2019)

Volume 147, Issue 1, Pages (October 2017)

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

Volume 139, Issue 3, Pages (December 2015)

Volume 152, Issue 1, Pages (January 2019)

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer Ana Belén Custodio, MD, José Luis González-Larriba,

Volume 142, Issue 2, Pages (August 2016)

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Volume 150, Issue 3, Pages (September 2018)

Volume 152, Issue 1, Pages (January 2019)

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

Radiofrequency Ablation for Stage I Non-Small Cell Lung Cancer: Management of Locoregional Recurrence Michael Lanuti, MD, Amita Sharma, MD, Henning Willers,

Volume 152, Issue 1, Pages (January 2019)

Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer M. Dandapani, B.L. Seagle, R. Samuelson,

Volume 130, Issue 1, Pages (July 2013)

Adjuvant Surgery after Carboplatin and VP16 in Resectable Small Cell Lung Cancer Giulia Veronesi, MD, Paolo Scanagatta, MD, Francesco Leo, MD, Tommaso.

Volume 124, Issue 1, Pages (January 2012)

Volume 154, Issue 1, Pages (July 2019)

Volume 115, Issue 1, Pages (October 2009)

624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results Molecular.

Presentation transcript:

Volume 148, Issue 1, Pages 79-85 (January 2018) Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients V. Heinzelmann-Schwarz, A. Knipprath Mészaros, S. Stadlmann, F. Jacob, A. Schoetzau, K. Russell, M. Friedlander, G. Singer, M. Vetter Gynecologic Oncology Volume 148, Issue 1, Pages 79-85 (January 2018) DOI: 10.1016/j.ygyno.2017.10.036 Copyright © 2017 The Authors Terms and Conditions

Fig. 1 ESR1 expression in TCGA dataset. Overall disease-free survival (A) and relapse-free survival (B) in the TCGA PANCAN dataset (Cohort A, Table 1) p-value (log rank test). (C) Box-Whisker blot ESR1 expression for anatomical origin sorted by descending median ESR1 expression among all TCGA cancer types; (D) ESR1 expression for histopathological grading and FIGO staging in the Tothill and TCGA data set for high-grade serous ovarian cancer samples (Cohort A, Table 1). (E) Barchart showing percentage of IHC results for ER and PR in HGSOC broken down into various sampling sites (Cohort B, Table 1). Gynecologic Oncology 2018 148, 79-85DOI: (10.1016/j.ygyno.2017.10.036) Copyright © 2017 The Authors Terms and Conditions

Fig. 2 Relapse-free survival of HGSOC FIGO III/IV treated with/without Letrozole as a maintenance therapy. Letrozole treated (red line; n=23) vs untreated group (black line; n=27), showing a significantly longer relapse-free survival when using Letrozole (p=0.035). RFS is defined from the end of adjuvant chemotherapy till first symptomatic recurrence, confirmed by RECIST. IC50 not reached in the Letrozole vs untreated group (13.2months) (Cohort D; Table 1). Gynecologic Oncology 2018 148, 79-85DOI: (10.1016/j.ygyno.2017.10.036) Copyright © 2017 The Authors Terms and Conditions

Fig. 3 Relapse-free survival of HGSOC FIGO III/IV treated with Bevacizumab as a maintenance therapy. Letrozole treated (red line; n=9) vs untreated group (black line; n=6), showing a significantly longer relapse-free survival when using Letrozole in combination with Bevacizumab in patients with residual disease (p=0.026). RFS is time from end of adjuvant chemotherapy until first symptomatic relapse as confirmed by RECIST. Gynecologic Oncology 2018 148, 79-85DOI: (10.1016/j.ygyno.2017.10.036) Copyright © 2017 The Authors Terms and Conditions